…
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | -14.14M | -14.24M | -6.59M | -4.77M | -4.45M |
| Net income | -25.10M | -13.89M | -6.26M | -4.16M | -4.45M |
| Selling general administrative | 5.60M | 6.17M | 3.03M | 2.77M | 2.18M |
| Gross profit | -1.48M | 0.16M | - | - | - |
| Reconciled depreciation | 0.44M | 0.23M | 0.10M | 0.05M | 0.03M |
| Ebit | -9.60M | -7.57M | -4.59M | -4.78M | -4.48M |
| Ebitda | -8.17M | -7.34M | -4.49M | -4.72M | -4.44M |
| Depreciation and amortization | 1.42M | 0.23M | 0.10M | 0.05M | 0.03M |
| Non operating income net other | - | - | - | 0.00M | 0.02M |
| Operating income | -9.60M | -7.57M | -4.59M | -4.78M | -4.48M |
| Other operating expenses | 8.69M | 8.07M | 4.59M | 4.78M | 4.48M |
| Interest expense | 6.41M | 6.67M | 2.01M | 0.00M | 0.00M |
| Tax provision | 0.00M | -0.35M | -0.34M | -0.61M | - |
| Interest income | - | - | - | 0.00M | 0.02M |
| Net interest income | -6.41M | -6.67M | -2.01M | 0.00M | 0.02M |
| Income tax expense | 10.96M | -0.35M | -0.34M | -0.61M | 0.02M |
| Total revenue | 0.08M | 0.50M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 7.14M | 7.73M | 4.59M | 4.78M | 4.48M |
| Cost of revenue | 1.55M | 0.34M | - | - | - |
| Total other income expense net | -4.55M | -6.67M | -2.01M | 0.00M | 0.02M |
| Net income from continuing ops | -14.14M | -13.89M | -6.26M | -4.16M | -4.45M |
| Net income applicable to common shares | -14.14M | -13.89M | -6.26M | -4.16M | -4.45M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 14.56M | 22.10M | 35.24M | 1.22M | 4.76M |
| Intangible assets | 0.38M | 1.48M | 1.06M | 0.21M | 0.19M |
| Other current assets | 0.36M | 0.47M | 1.18M | 0.45M | 0.74M |
| Total liab | 26.38M | 21.64M | 26.88M | 2.53M | 2.54M |
| Total stockholder equity | -11.81M | 0.47M | 8.36M | -1.31M | 2.23M |
| Deferred long term liab | - | - | 1.28M | 1.15M | 1.24M |
| Other current liab | 4.88M | 1.00M | 0.33M | 0.08M | 0.11M |
| Common stock | 0.03M | 0.02M | 0.02M | 0.02M | 0.21M |
| Capital stock | 0.03M | 0.02M | 0.02M | 0.02M | 0.21M |
| Retained earnings | -51.88M | -37.73M | -23.84M | -17.59M | -13.43M |
| Other liab | 1.02M | 1.05M | 1.28M | 1.15M | 1.24M |
| Cash | 10.11M | 17.75M | 31.87M | 0.11M | 3.74M |
| Total current liabilities | 22.27M | 20.58M | 6.42M | 1.39M | 1.30M |
| Current deferred revenue | 0.12M | 0.26M | 0.10M | 0.09M | 0.07M |
| Net debt | 9.93M | 1.44M | -6.94M | -0.11M | -3.74M |
| Short term debt | 16.94M | 19.19M | 5.73M | 0.92M | 0.96M |
| Short long term debt | 16.94M | 19.19M | 5.73M | - | - |
| Short long term debt total | 20.03M | 19.19M | 24.92M | 0.08M | - |
| Other stockholder equity | 40.99M | 38.30M | 32.04M | 16.59M | 15.47M |
| Property plant equipment | 0.64M | 0.53M | 0.20M | 0.16M | 0.06M |
| Total current assets | 13.54M | 20.09M | 33.99M | 0.84M | 4.52M |
| Net tangible assets | -12.20M | -1.01M | 8.36M | -1.53M | 2.04M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | 0.41M | 0.38M | 0.09M | 0.10M | 0.21M |
| Long term debt | 3.09M | - | 19.19M | - | - |
| Inventory | 1.75M | 1.49M | 0.85M | 0.29M | 0.04M |
| Accounts payable | 0.33M | 0.14M | 0.25M | 0.29M | 0.16M |
| Accumulated other comprehensive income | -0.96M | -0.12M | 0.14M | -0.34M | -0.34M |
| Common stock total equity | - | - | 0.02M | 0.02M | 0.21M |
| Retained earnings total equity | - | - | -23.84M | -17.59M | -13.43M |
| Non currrent assets other | - | - | 0.00M | 0.38M | 0.25M |
| Non current assets total | 1.03M | 2.01M | 1.26M | 0.38M | 0.25M |
| Long term debt total | - | - | 19.19M | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -0.54M | -0.96M | -0.84M | -0.21M | 4.40M |
| Change to liabilities | 0.19M | -0.12M | -0.63M | 0.15M | 0.82M |
| Total cashflows from investing activities | -0.54M | -0.96M | -0.84M | -0.21M | 4.40M |
| Net borrowings | -5.57M | -12.40M | 22.87M | -0.04M | -0.04M |
| Total cash from financing activities | 2.08M | -6.37M | 37.99M | 0.10M | 2.05M |
| Change to operating activities | -0.33M | 0.83M | -1.35M | 0.20M | 0.33M |
| Net income | -14.14M | -13.89M | -6.26M | -4.16M | -4.45M |
| Change in cash | -7.64M | -14.12M | 31.76M | -3.63M | 2.92M |
| Begin period cash flow | 17.75M | 31.87M | 0.11M | 3.74M | 0.82M |
| End period cash flow | 10.11M | 17.75M | 31.87M | 0.11M | 3.74M |
| Total cash from operating activities | -8.45M | -6.50M | -6.00M | -3.45M | -3.56M |
| Issuance of capital stock | 8.39M | 3.12M | 15.75M | 0.15M | 2.47M |
| Depreciation | 0.44M | 0.23M | 0.10M | 0.05M | 0.03M |
| Other cashflows from investing activities | - | - | -0.75M | -0.05M | 4.46M |
| Change to inventory | -1.75M | -0.64M | -0.56M | -0.26M | -0.04M |
| Change to account receivables | 0.58M | -0.25M | -0.68M | -0.68M | -2.88M |
| Sale purchase of stock | - | - | 16.15M | 0.18M | 2.54M |
| Other cashflows from financing activities | 3.96M | 2.91M | 22.84M | -0.01M | -0.42M |
| Change to netincome | 5.43M | 0.66M | 0.11M | 0.58M | 0.46M |
| Capital expenditures | 0.54M | 0.96M | 0.84M | 0.21M | 0.08M |
| Change receivables | - | - | - | -0.26M | 0.07M |
| Cash flows other operating | - | - | -0.77M | 0.19M | -0.46M |
| Cash and cash equivalents changes | - | - | 31.15M | -3.56M | 2.89M |
| Change in working capital | -2.05M | -0.17M | -1.96M | 0.08M | 0.39M |
| Stock based compensation | 0.00M | 0.22M | 0.11M | 0.57M | 0.43M |
| Other non cash items | 7.30M | 7.11M | 2.01M | 0.01M | 0.03M |
| Free cash flow | -8.99M | -7.46M | -6.83M | -3.66M | -3.64M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NMRD Nemaura Medical Inc |
- -% |
0.00 | - | - | 766.31 | 122.56 | 7183.65 | -4.88 |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Dr. Dewan Fazlul Hoque Chowdhury Ph.D. | Chairman, CEO, Pres, Principal Financial Officer & Principal Accounting Officer | 1973 |
| Dr. Arash Ghadar | Chief Operating Officer | 1977 |
| Mr. Bashir Timol | Chief Bus. Officer & Director | 1974 |
| Mr. Jay L. Warner | Head of U.S. Commercial Operations | NA |
| Mr. Thomas Bendix Mortensen | Head of E.U. Commercial Operations & Marketing | NA |
| Ms. Samantha Sanders | Global Head of Digital Programs | NA |
| Dr. Dewan Fazlul Hoque Chowdhury Ph.D. | Chairman, Interim CFO, CEO, President and Principal Financial & Accounting Officer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.